How to buy Vertex Pharmaceuticals Incorporated (VRTX) shares in Australia

Learn how to easily invest in Vertex Pharmaceuticals Incorporated shares.

Vertex Pharmaceuticals Incorporated
NASDAQ: VRTX - USD
BIOTECHNOLOGY
$185.99
+ $1.00 ( + 0.54%)

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!

Vertex Pharmaceuticals Incorporated (VRTX) is a leading biotechnology business with stocks listed in the US. It opened the day at US$186.24 after a previous close of US$187.1. During the day the price has varied from a low of USD184.78 to a high of USD188.535. The latest price was USD188.3 (25 minute delay). Vertex Pharmaceuticals Incorporated is listed on the NASDAQ. All prices are listed in US Dollars.

How to buy shares in Vertex Pharmaceuticals Incorporated

  1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Vertex Pharmaceuticals Incorporated. Find the share by name or ticker symbol: VRTX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Vertex Pharmaceuticals Incorporated reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of US$187.1, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Vertex Pharmaceuticals Incorporated, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Vertex Pharmaceuticals Incorporated. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Vertex Pharmaceuticals Incorporated stock price (NASDAQ:VRTX)

Use our graph to track the performance of VRTX stocks over time.

Vertex Pharmaceuticals Incorporated shares at a glance

Information last updated 2021-09-17.
OpenUS$186.24
HighUS$188.535
LowUS$184.78
CloseUS$188.3
Previous closeUS$187.1
Change US$1.2
Change % 0.6414%
Volume 2,214,404
Information last updated 2021-10-23.
52-week rangeUS$176.36 - US$242.99
50-day moving average US$184.4706
200-day moving average US$199.6222
Target priceUS$258.45
PE ratio 24.1951
Dividend yield N/A (0%)
Earnings per share (TTM) US$7.585

Where to buy Vertex Pharmaceuticals Incorporated stock

Name Product Standard brokerage for US shares Currency conversion fee Markets
eToro (global stocks)
US$0
50 pips (US$0.50 for every AU$100 exchanged)
Global shares, US shares, ETFs
Zero brokerage share trading on US, Hong Kong and European stocks with trades as low as $50.
Note: This broker offers CFDs which are volatile investment products and most clients lose money trading CFDs with this provider.
Join the world’s biggest social trading network when you trade stocks, commodities and currencies from the one account.
IG Share Trading
US$0
0.70%
ASX shares, Global shares
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.
Superhero share trading
US$0
50 pips (US$0.50 for every AU$100 exchanged)
ASX shares, US shares
Australia’s lowest-cost broker for ASX shares and ETFs.
Pay zero brokerage on US stocks and all ETFs and just $5 (flat fee) to trade Australian shares from your mobile or desktop.
SelfWealth (Basic account)
US$9.5
0.60%
ASX shares, US shares
Trade ASX and US shares for a flat fee of $9.50, regardless of the trade size.
New customers receive free access to Community Insights with SelfWealth Premium for the first 90 days. Follow other investors and benchmark your portfolio performance.
Saxo Capital Markets (Classic account)
US$4
1%
ASX shares, Global shares, Forex, CFDs, Margin trading, Options trading, ETFs
Access 19,000+ stocks on 40+ exchanges worldwide
Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.
CMC Markets Invest
US$0
0.60%
ASX shares, Global shares, mFunds, ETFs
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 9,000 products, including shares, ETFs and managed funds, plus access up to 15 major global and Australian stock exchanges.
loading

Compare up to 4 providers

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Vertex Pharmaceuticals Incorporated stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Vertex Pharmaceuticals Incorporated share growth calculator

US$

Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.

Considering buying Vertex Pharmaceuticals Incorporated shares?

Before you consider Vertex Pharmaceuticals Incorporated, you'll want to hear this.
Ticker Nerd uses advanced software to track hundreds of signals and data points to find stocks before they blow up. You can get the next two hot stocks they find sent to your inbox for free.

Show me how

Vertex Pharmaceuticals Incorporated price performance over time

Historical closes compared with the last close of $188.3

1 week (2021-10-18) 4.15%
1 month (2021-09-24) 2.55%
3 months (2021-07-26) -5.34%
6 months (2021-04-26) -13.21%
1 year (2020-10-26) -9.10%
2 years (2019-10-25) -3.18%
3 years (2018-10-26) 11.10%
5 years (2016-10-26) 139.23%

Stocks similar to Vertex Pharmaceuticals Incorporated

Is Vertex Pharmaceuticals Incorporated under- or over-valued?

Valuing Vertex Pharmaceuticals Incorporated stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Vertex Pharmaceuticals Incorporated's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Vertex Pharmaceuticals Incorporated's P/E ratio

Vertex Pharmaceuticals Incorporated's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 24x. In other words, Vertex Pharmaceuticals Incorporated shares trade at around 24x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Vertex Pharmaceuticals Incorporated's PEG ratio

Vertex Pharmaceuticals Incorporated's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.2852. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Vertex Pharmaceuticals Incorporated's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Vertex Pharmaceuticals Incorporated's EBITDA

Vertex Pharmaceuticals Incorporated's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$2.4 billion (£1.7 billion).

The EBITDA is a measure of a Vertex Pharmaceuticals Incorporated's overall financial performance and is widely used to measure a its profitability.

Vertex Pharmaceuticals Incorporated financials

Revenue TTM US$6.7 billion
Operating margin TTM 33.93%
Gross profit TTM US$3.6 billion
Return on assets TTM 12.63%
Return on equity TTM 23.83%
Profit margin 29.8%
Book value 35.492
Market capitalisation US$48.5 billion

TTM: trailing 12 months

Shorting Vertex Pharmaceuticals Incorporated shares

There are currently 5.1 million Vertex Pharmaceuticals Incorporated shares held short by investors – that's known as Vertex Pharmaceuticals Incorporated's "short interest". This figure is 2.2% up from 5.0 million last month.

There are a few different ways that this level of interest in shorting Vertex Pharmaceuticals Incorporated shares can be evaluated.

Vertex Pharmaceuticals Incorporated's "short interest ratio" (SIR)

Vertex Pharmaceuticals Incorporated's "short interest ratio" (SIR) is the quantity of Vertex Pharmaceuticals Incorporated shares currently shorted divided by the average quantity of Vertex Pharmaceuticals Incorporated shares traded daily (recently around 1.4 million). Vertex Pharmaceuticals Incorporated's SIR currently stands at 3.72. In other words for every 100,000 Vertex Pharmaceuticals Incorporated shares traded daily on the market, roughly 3720 shares are currently held short.

However Vertex Pharmaceuticals Incorporated's short interest can also be evaluated against the total number of Vertex Pharmaceuticals Incorporated shares, or, against the total number of tradable Vertex Pharmaceuticals Incorporated shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Vertex Pharmaceuticals Incorporated's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Vertex Pharmaceuticals Incorporated shares in existence, roughly 20 shares are currently held short) or 0.0196% of the tradable shares (for every 100,000 tradable Vertex Pharmaceuticals Incorporated shares, roughly 20 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Vertex Pharmaceuticals Incorporated.

Find out more about how you can short Vertex Pharmaceuticals Incorporated stock.

Vertex Pharmaceuticals Incorporated's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Vertex Pharmaceuticals Incorporated.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Vertex Pharmaceuticals Incorporated's total ESG risk score

Total ESG risk: 30.84

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Vertex Pharmaceuticals Incorporated's overall score of 30.84 (as at 12/31/2018) is nothing to write home about – landing it in it in the 44th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Vertex Pharmaceuticals Incorporated is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Vertex Pharmaceuticals Incorporated's environmental score

Environmental score: 5.65/100

Vertex Pharmaceuticals Incorporated's environmental score of 5.65 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Vertex Pharmaceuticals Incorporated is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Vertex Pharmaceuticals Incorporated's social score

Social score: 24.22/100

Vertex Pharmaceuticals Incorporated's social score of 24.22 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Vertex Pharmaceuticals Incorporated is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Vertex Pharmaceuticals Incorporated's governance score

Governance score: 12.46/100

Vertex Pharmaceuticals Incorporated's governance score puts it squarely in the 8th percentile of companies rated in the same sector. That could suggest that Vertex Pharmaceuticals Incorporated is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Vertex Pharmaceuticals Incorporated's controversy score

Controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Vertex Pharmaceuticals Incorporated scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Vertex Pharmaceuticals Incorporated has, for the most part, managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Vertex Pharmaceuticals Incorporated was last rated for ESG on: 2019-01-01.

Total ESG score 30.84
Total ESG percentile 44
Environmental score 5.65
Environmental score percentile 8
Social score 24.22
Social score percentile 8
Governance score 12.46
Governance score percentile 8
Level of controversy 2

Vertex Pharmaceuticals Incorporated share dividends

We're not expecting Vertex Pharmaceuticals Incorporated to pay a dividend over the next 12 months.

Have Vertex Pharmaceuticals Incorporated's shares ever split?

Vertex Pharmaceuticals Incorporated's shares were split on a 2:1 basis on 23 August 2000. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Vertex Pharmaceuticals Incorporated shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Vertex Pharmaceuticals Incorporated shares which in turn could have impacted Vertex Pharmaceuticals Incorporated's share price.

Vertex Pharmaceuticals Incorporated share price volatility

Over the last 12 months, Vertex Pharmaceuticals Incorporated's shares have ranged in value from as little as US$176.36 up to US$242.99. A popular way to gauge a stock's volatility is its "beta".

VRTX.US volatility(beta: 0.66)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vertex Pharmaceuticals Incorporated's is 0.6566. This would suggest that Vertex Pharmaceuticals Incorporated's shares are less volatile than average (for this exchange).

Vertex Pharmaceuticals Incorporated overview

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics, as well as a strategic research collaboration and licensing agreement with Obsidian Therapeutics, Inc. for the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site